Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Current Role of Endocrine Therapy in Locally Advanced Breast Cancer to Improve Breast Conservation Rates

The Current Role of Endocrine Therapy in Locally Advanced Breast Cancer to Improve Breast... The use of neoadjuvant therapy is well established in the treatment of the breast cancer, and neoadjuvant endocrine therapy is emerging as a safe and an effective alternative to chemotherapy in selected patients with a hormone receptor–positive locally advanced breast cancer without compromising survival rates. Neoadjuvant endocrine therapy increases the rate of breast conservative surgery in women initially requiring mastectomy, and the latest generation of endocrine therapy, the aromatase inhibitors, has been proved to be superior to tamoxifen. Biomarkers such as Ki67, estrogen receptor, and the PEPI index can be used to select and monitor patients if neoadjuvant endocrine therapy is considered. Biomarkers can give predictive information in weeks, and alternative treatment can be considered before or after surgical resection. The benefits of the neoadjuvant approach are not only tumor size reduction to improve surgical approach, but also to better understand the impact of the treatment on the tumor and treatment resistance due to tumor heterogeneity. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Breast Cancer Reports Springer Journals

The Current Role of Endocrine Therapy in Locally Advanced Breast Cancer to Improve Breast Conservation Rates

Loading next page...
 
/lp/springer-journals/the-current-role-of-endocrine-therapy-in-locally-advanced-breast-0vUnakd1yq
Publisher
Springer Journals
Copyright
Copyright © 2012 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Internal Medicine; Surgical Oncology; Oncology
ISSN
1943-4588
eISSN
1943-4596
DOI
10.1007/s12609-012-0077-5
Publisher site
See Article on Publisher Site

Abstract

The use of neoadjuvant therapy is well established in the treatment of the breast cancer, and neoadjuvant endocrine therapy is emerging as a safe and an effective alternative to chemotherapy in selected patients with a hormone receptor–positive locally advanced breast cancer without compromising survival rates. Neoadjuvant endocrine therapy increases the rate of breast conservative surgery in women initially requiring mastectomy, and the latest generation of endocrine therapy, the aromatase inhibitors, has been proved to be superior to tamoxifen. Biomarkers such as Ki67, estrogen receptor, and the PEPI index can be used to select and monitor patients if neoadjuvant endocrine therapy is considered. Biomarkers can give predictive information in weeks, and alternative treatment can be considered before or after surgical resection. The benefits of the neoadjuvant approach are not only tumor size reduction to improve surgical approach, but also to better understand the impact of the treatment on the tumor and treatment resistance due to tumor heterogeneity.

Journal

Current Breast Cancer ReportsSpringer Journals

Published: Apr 13, 2012

References